GENE POLYMORPHISMS AS PREDICTORS OF TREATMENT EFFICACY AND TOXICITY IN PATIENTS WITH INDOLENT NON‐HODGKIN LYMPHOMAS RECEIVING BENDAMUSTINE AND RITUXIMAB. (June 2017)